Resumen
Las alteraciones del metabolismo lipídico incrementan el riesgo cardiovascular. Desafortunadamente, en los últimos años se está observando un aumento de la prevalencia de la dislipemia en España. La concomitancia de dislipemia y otros factores de riesgo como hipertensión arterial, diabetes mellitus, síndrome metabólico, tabaquismo o enfermedad renal es muy frecuente e incrementa marcadamente los eventos cardiovasculares. Sin embargo, cada factor de riesgo modifica el perfil lipídico de una manera específica. Es importante conocer los cambios concretos en los lípidos asociados a cada factor de riesgo para así poder realizar una aproximación terapéutica específica en cada paciente. El objetivo de esta revisión es actualizar la relación existente entre las alteraciones del metabolismo lipídico y los otros factores de riesgo y cuál es la mejor aproximación en cada situación.
Palabras clave
Lípidos
Colesterol
Triglicéridos
Factores de riesgo
Hipertensión
Diabetes mellitus
Síndrome metabólico
Insuficiencia renal
Tabaquismo
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
Villar Álvarez F, Banegas Banegas JR, Donado Campos J, Rodríguez Artalejo F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2007. Sociedad Española De Arteriosclerosis. Disponible en: http://www.searteriosclerosis.com/web/contenidos/secciones/71/informe-sea-2007
[2.]
J.R. Banegas, F. Villar, C. Pérez, R. Jiménez, E. Gil, J. Muñiz, et al.
Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años.
Rev San Hig Pub, (1993), 67 pp. 419-445
[3.]
M.J. Medrano, E. Cerrato, R. Boix, M. Delgado-Rodríguez.
Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales.
Med Clin (Barc), (2005), 124 pp. 606-612
[4.]
O. Vegazo, J.R. Banegas, F. Civeira, P. Serrano, E. Luengo, T. Mantilla.
Prevalencia de las dislipemias en consultas ambulatorias del sistema sanitario español. Estudio Hispalipid.
Med Clin (Barc), (2006), 127 pp. 331-334
[5.]
V. Barrios, M. Martínez, J.P. Tomás, I. Herranz, L. Prieto, J.L. Llisterri, et al.
Perfil clínico de una población hipercolesterolémica española y diferencias entre sexos. Estudio LIPYCARE.
Hipertensión, (2004), 21 pp. 395-402
[6.]
A. López Suárez, J. Elvira González, M. Beltrán Robles, M. Alwakil, J.M. Saucedo, A. Bascuñana Quirell, et al.
Prevalencia de obesidad, diabetes, hipertensión, hipercolesterolemia y síndrome metabólico en adultos mayores de 50 años de Sanlúcar de Barrameda.
Rev Esp Cardiol, (2008), 61 pp. 1150-1158
[7.]
V. Capuano, A. Bambacaro, T. D’Arminio, B. Del Regno, V. Dantonio, C. Lanzara.
Changes in total serum cholesterol for cardiovascular disease in a Mediterranean area, 1989–1999.
Eur J Epidemiol, (2003), 18 pp. 27-32
[8.]
British Heart Foundation.
European Cardiovascular Disease Statistics 2008.
British Heart Foundation, (2008),
[9.]
Informe Sociedad Española de Cardiología 2009. Fuente: Instituto Nacional de Estadística. Defunciones según la Causa de Muerte 2007. Madrid: Instituto Nacional de Estadística; 2009 [citado Oct 2009]. Disponible en: www.ine.es
[10.]
S. Sans, A. Puigdefábregas, G. Paluzie, D. Monterde, I. Balaguer-Vintró.
Increasing trends of acute myocardial infarction in Spain: the MONICA Catalonia Study.
Eur Heart J, (2005), 26 pp. 505-515
[11.]
M. Gil, H. Martí, R. Elosúa, M. Grau, J. Sala, R. Masiá, et al.
Análisis de la tendencia en la letalidad, incidencia y mortalidad por infarto de miocardio en Girona entre 1990 y 1999.
Rev Esp Cardiol, (2007), 60 pp. 349-356
[12.]
J.D. Neaton, H. Blackburn, D. Jacobs, L. Kuller, D.J. Lee, R. Sherwin, et al.
Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial.
Arch Intern Med, (1992), 152 pp. 1490-1500
[13.]
W.B. Kannel, W.P. Castelli, T. Gordon, P.M. McNamara.
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Ann Intern Med, (1971), 74 pp. 1-12
[14.]
I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, et al.
European guidelines on cardiovascular disease prevention in clinical practice: executive summary.
Eur Heart J, (2007), 28 pp. 2375-2414
[15.]
C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, Cholesterol Treatment Trialists’ (CTT) Collaborators, et al.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Lancet, (2005), 366 pp. 1267-1278
[16.]
S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, INTERHEART Study Investigators, et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
Lancet, (2004), 364 pp. 937-952
[17.]
V. Barrios, C. Escobar, V. Bertomeu, N. Murga, C. De Pablo, A. Calderón.
Control de los factores de riesgo en los pacientes hipertensos con cardiopatía isquémica crónica atendidos en las consultas de cardiología. Estudio CINHTIA.
Rev Clin Esp, (2008), 208 pp. 400-404
[18.]
V. Barrios, C. Escobar, J.L. Llisterri, A. Calderón, E. Alegría, J. Muñiz, et al.
Control de presión arterial y lípidos y riesgo coronario en la población hipertensa asistida en Atención Primaria en España. Estudio PRESCOT.
Rev Clin Esp, (2007), 207 pp. 172-178
[19.]
Heart Protection Study Group.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebo-controlled trial.
Lancet, (2002), 360 pp. 7-22
[20.]
J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, PROSPER study group, et al.
PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Lancet, (2002), 360 pp. 1623-1630
[21.]
P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, A.E. Rudolph, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, et al.
High-dose atorvastatin after stroke or transient ischemic attack.
N Engl J Med, (2006), 355 pp. 549-559
[22.]
P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, ASCOT investigators, et al.
The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT: LLA).
Lancet, (2003), 361 pp. 1149-1158
[23.]
The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group.
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
JAMA, (2002), 288 pp. 2998-3007
[24.]
G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, et al.
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens, (2007), 25 pp. 1105-1187
[25.]
S.A. Chang, Y.J. Kim, H.W. Lee, D.H. Kim, H.K. Kim, H.J. Chang, et al.
Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy.
Hypertension, (2009), 54 pp. 591-597
[26.]
J. Emberson, P. Whincup, R. Morris, M. Walker, S. Ebrahim.
Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease.
Eur Heart J, (2004), 25 pp. 484-491
[27.]
R. Gabriel, M. Alonso, A. Segura, M.J. Tormo, L.M. Artigao, J.R. Banegas, et al.
Prevalencia, distribución y variabilidad geográfica de los principales factores de riesgo cardiovascular en España. Análisis agrupado de datos individuales de estudios epidemiológicos poblacionales: estudio ERICE.
Rev Esp Cardiol, (2008), 61 pp. 1030-1040
[28.]
S. Valdés, P. Botas, E. Delgado, F. Díaz Cadórniga.
Riesgo de mortalidad en diabetes diagnosticada, diabetes no diagnosticada y prediabetes en población adulta española. Estudio Asturias 1998–2004.
Rev Esp Cardiol, (2009), 62 pp. 528-534
[29.]
F. Cosentino, L. Rydén, P. Francia, L.G. Mellbin.
Diabetes mellitus and metabolic syndrome.
The ESC Textbook of Cardiovascular Medicine, 2.a ed., European Society of Cardiology, Oxford University Press, (2009),
[30.]
M.S. Gowri, D.R. Van der Westhuyzen, S.R. Bridges, J.W. Anderson.
Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL.
Arterioscler Thromb Vasc Biol, (1999), 19 pp. 2226-2233
[31.]
E.C. Tsai, I.B. Hirsch, J.D. Brunzell, A. Chait.
Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM.
Diabetes, (1994), 43 pp. 1010-1014
[32.]
S.M. Haffner, C.M. Alexander, T.J. Cook, S.J. Boccuzzi, T.A. Musliner, T.R. Pedersen, et al.
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
Arch Intern Med, (1999), 159 pp. 2661-2667
[33.]
R.B. Goldberg, M.J. Mellies, F.M. Sacks, L.A. Moyé, B.V. Howard, W.J. Howard, et al.
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
Circulation, (1998), 98 pp. 2513-2519
[34.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, (2004), 350 pp. 1495-1504
[35.]
J. Shepherd, P. Barter, R. Carmena, P. Deedwania, J.C. Fruchart, S. Haffner, et al.
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Diabetes Care, (2006), 29 pp. 1220-1226
[36.]
H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Lancet, (2004), 364 pp. 685-696
[37.]
S. Giunti, A.C. Calkin, J.M. Forbes, T.J. Allen, M.C. Thomas, M.E. Cooper, et al.
The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Am J Physiol Renal Physiol, (2010), 299 pp. F528-F535
[38.]
C. Zoja, D. Corna, E. Gagliardini, S. Conti, L. Arnaboldi, A. Benigni, et al.
Adding a statin to a combination of ace inhibitor and arb normalizes proteinuria in experimental diabetes which translates into full renoprotection.
Am J Physiol Renal Physiol, (2010),
[39.]
H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, et al.
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
N Engl J Med, (1999), 341 pp. 410-418
[40.]
A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, et al.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Lancet, (2005), 366 pp. 1849-1861
[41.]
H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse 3rd, L.A. Leiter, ACCORD Study Group, et al.
Effects of combination lipid therapy in type 2 diabetes mellitus.
N Engl J Med, (2010), 362 pp. 1563-1574
[42.]
A.J. Taylor, T.C. Villines, E.J. Stanek, P.J. Devine, L. Griffen, M. Miller, et al.
Extendedrelease niacin or ezetimibe and carotid intima-media thickness.
N Engl J Med, (2009), 361 pp. 2113-2122
[43.]
S.M. Grundy, H.B. Brewer Jr, J.I. Cleeman, S.C. Smith Jr, C. Lenfant.
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
Circulation, (2004), 109 pp. 433-438
[44.]
K.G. Alberti, P. Zimmet, J. Shaw.
The metabolic syndrome — a new worldwide definition.
Lancet, (2005), 366 pp. 1059-1062
[45.]
H.N. Ginsberg, Y.L. Zhang, A. Hernandez-Ono.
Metabolic syndrome: Focus on dyslipidemia.
Obesity (Silver Spring), (2006), 14 pp. S41-S49
[46.]
H.B. Rubins.
Triglycerides and coronary heart disease: implications of recent clinical trials.
J Cardiovasc Risk, (2000), 7 pp. 339-345
[47.]
L. Erhardt.
Cigarette smoking: an undertreated risk factor for cardiovascular disease.
Atherosclerosis, (2009), 205 pp. 23-32
[48.]
W.Y. Craig, G.E. Palomaki, J.E. Haddow.
Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data.
BMJ, (1989), 298 pp. 784-788
[49.]
D.G. Yanbaeva, M.A. Dentener, E.C. Creutzberg, G. Wesseling, E.F. Wouters.
Systemic effects of smoking.
Chest, (2007), 131 pp. 1557-1566
[50.]
K. Sirisali, T. Kanluan, N. Poungvarin, C. Prabhant.
Serum lipid, lipoprotein-cholesterol and apolipoproteins A-I and B of smoking and non-smoking males.
J Med Assoc Thai, (1992), 75 pp. 709-713
[51.]
J. Whig, C.B. Singh, G.L. Soni, A.K. Bansal.
Serum lipids & lipoprotein profiles of cigarette smokers & passive smokers.
Indian J Med Res, (1992), 96 pp. 282-287
[52.]
W.Y. Craig, G.E. Palomaki, A.M. Johnson, J.E. Haddow.
Cigarette smoking-associated changes in blood lipid and lipoprotein levels in the 8- to 19-year-old age group: a meta-analysis.
Pediatrics, (1990), 85 pp. 155-158
[53.]
N.D. Vaziri.
Causes of dysregulation of lipid metabolism in chronic renal failure.
Semin Dial, (2009), 22 pp. 644-651
[54.]
T. Quaschning, V. Krane, T. Metzger, C. Wanner.
Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
Am J Kidney Dis, (2001), 38 pp. S14-S19
[55.]
C. Wanner, V. Krane, W. März, M. Olschewski, J.F. Mann, G. Ruf, German Diabetes and Dialysis Study Investigators, et al.
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
N Engl J Med, (2005), 353 pp. 238-248
[56.]
B.C. Fellström, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, AURORA Study Group, et al.
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
N Engl J Med, (2009), 360 pp. 1395-1407
[57.]
P.M. Ridker, J. MacFadyen, M. Cressman, R.J. Glynn.
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
J Am Coll Cardiol, (2010), 55 pp. 1266-1273
[58.]
V. Barrios, C. Escobar.
Rosuvastatin and cardiovascular continuum when time is important.
J Am Coll Cardiol, (2010), 55 pp. 1645-1646
Copyright ©
2011. Sociedad Española de Cardiología